drugs for the treatment of chronic diseases
of the skin.
The core business focus of Scioderm is the development of innovative dermatological drugs.
Our strategy is to in-license or acquire early to mid-stage pharmaceutical products with the intent to develop the topical products. The Scioderm team will evaluate the target assets and execute the agreements and necessary strategy to support in- and out-licensing, acquisition, strategic alliance and equity investment transactions.
The Scioderm team targets assets and prepares and implements the optimum strategy to develop these products for commercial success. The team will continually seek new opportunities for in-license or partnering, interested in opportunities that have a well-validated target, a novel mechanism of action, well-characterized pharmaceutical properties, a strong intellectual property position and preclinical or clinical data.